8-K: Liquidia Corporation Sees Partial Dismissal in Patent Infringement Case, Awaits Court Decision on Injunction

Liquidia Corporation has had claims related to one patent dismissed in an ongoing patent infringement lawsuit with United Therapeutics, while awaiting a court decision on a separate injunction.

Summary

• Liquidia Corporation is involved in a patent infringement lawsuit with United Therapeutics regarding its drug YUTREPIA.
• United Therapeutics initially filed an amended complaint alleging infringement of two patents, the 793 Patent and the 327 Patent, related to the addition of the PH-ILD indication to YUTREPIA's label.
• On January 22, 2024, United Therapeutics dismissed all claims related to the 793 Patent, leaving only the claims related to the 327 Patent in the lawsuit.
• Liquidia believes that United Therapeutics is not entitled to a 30-month regulatory stay for the 327 Patent because it was not issued before the original NDA filing for YUTREPIA.
• The dismissal of the 793 Patent claims does not affect a separate injunction issued in a previous lawsuit from June 2020.
• Liquidia has requested the court to set aside the injunction from the previous lawsuit, and briefing on this request was completed on January 23, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document contains both positive and negative developments. The dismissal of one patent claim is positive, but the ongoing litigation and existing injunction create uncertainty.

Positives

• The dismissal of claims related to the 793 Patent is a positive development for Liquidia, reducing the scope of the ongoing litigation.
• Liquidia's position that United Therapeutics is not entitled to a 30-month regulatory stay could potentially expedite the market entry of YUTREPIA for the PH-ILD indication.

Negatives

• The lawsuit regarding the 327 Patent is still ongoing, creating uncertainty for Liquidia.
• The existing injunction from the previous lawsuit remains in effect, potentially delaying the launch of YUTREPIA.

Risks

• The ongoing litigation with United Therapeutics could result in further delays or restrictions on the commercialization of YUTREPIA.
• The court's decision on setting aside the injunction could have a significant impact on Liquidia's ability to launch YUTREPIA.
• There is a risk that the court could rule against Liquidia in the 327 Patent case.

Future Outlook

The company is awaiting the District Court's decision on their request to set aside the injunction from the original Hatch-Waxman litigation.

Industry Context

This legal development is significant in the pharmaceutical industry, where patent disputes are common and can significantly impact the market entry of generic or biosimilar drugs. The outcome of this case could set a precedent for future patent litigation under the Hatch-Waxman Act.

Comparison to Industry Standards

• Patent litigation is a common occurrence in the pharmaceutical industry, particularly under the Hatch-Waxman Act, where generic drug manufacturers challenge patents of branded drugs.
• Companies like Teva Pharmaceuticals, Mylan (now Viatris), and Sandoz are frequently involved in similar patent disputes.
• The 30-month regulatory stay is a key aspect of the Hatch-Waxman Act, and the interpretation of when it applies is often a point of contention in these cases.
• The outcome of this case will be closely watched by other companies in the pharmaceutical industry facing similar patent challenges.

Legal Proceedings

• Liquidia is involved in a patent infringement lawsuit with United Therapeutics.
• The lawsuit concerns the infringement of U.S. Patent No. 11,826,327 related to the PH-ILD indication for YUTREPIA.
• United Therapeutics dismissed claims related to U.S. Patent No. 10,716,793.
• Liquidia has requested the court to set aside an injunction from a previous lawsuit.

Stakeholder Impact

• Shareholders may experience volatility in the stock price due to the ongoing litigation.
• The outcome of the litigation could impact the potential revenue and profitability of Liquidia.
• The delay in the launch of YUTREPIA could affect patients who could benefit from the drug.

Next Steps

• Liquidia will await the District Court's decision on their request to set aside the injunction.
• The company will continue to litigate the claims related to the 327 Patent.

Key Dates

Keywords

Liquidia, United Therapeutics, YUTREPIA, patent infringement, Hatch-Waxman Act, PH-ILD, injunction, litigation, regulatory stay, NDA